Meiji Seika Kaisha, Ltd.

Michio Kojima

Takashi Shomura

Hiroshi Watanabe

Shigeharu Inouye

Taro Niida

Yasuaki Ogawa

Kazunori Ohba

Takashi Tsuruoka

Shigeharu Inoue

Tomizo Niwa

Norio Ezaki

Shoji Omoto

Takashi Hisamatsu

Yasumitsu Kondo

Tatsuo Ito

Yujiro Yamada

Shingo Uchida

Kazuo Saito, Deceased

Katsuyoshi Iwamatsu

Masaji Sezaki

Shoichi Amano

Kunikazu Totsukawa

Shigeharu Inoje

An antibiotic SF-2103A substance or a salt thereof, and a process for the production thereof are described, and the process comprises cultivating an antibiotic SF-2103A substance-producing strain in a nutrient medium and recovering the desired substance from the culture broth.

Antibiotic SF-2103A substance and process for production thereof

Disclosed is a novel antibiotic SF-2107 series substance consisting essentially of Substance SF-2107 A-1, Substance SF-2107 B and/or Substance SF-2107 C, each having the phisico-chemical properties as described in the specification, which substance exhibits an antibacterial activity against both gram-positive and gram-negative bacteria and is useful for pharmaceuticals, bactericides, disinfectants, etc. Also disclosed is a process for preparing the substance.

Novel antibiotic SF-2107 series substance and process for preparing the

Antibiotics, designated as SF-2080A substance and SF-2080B substance, are described, and are obtained by cultivating an SF-2080 substance-producing strain belonging to the genus Streptomyces, for example, Streptomyces sp. SF-2080 (FERM-P No. 5072, ATCC No. 31673), in a nutrient medium, and recovering the desired substance from the culture.

Antibiotic substances and processes for production thereof

New antibiotic, SF-2052 substance is produced by cultivating a microorganism, Dactylosporangium matsuzakiense SF-2052 now deposited under FERM-P 4670 or ATCC No. 31570 in a liquid culture medium under aerobic conditions, and this antibiotic may be isolated from the culture broth by conventional method and is useful as antibacterial agent.

Antibiotic SF-2052 substance and production and use thereof

Substance SF-1739 derivatives, Substance SF-1739 HP, Substance SF-1739 HP-C, Substance SF-1739 HP-F, Substance SF-1739 HP-3 and Substance SF-1739 HP-5, the physico-chemical properties of which derivatives are described in the specification; processes for preparing such SF-1739 derivatives; and antimicrobial compositions containing at least one of the said Substance SF-1739 derivatives.

Substance SF-1739 derivatives, process for preparing the same and

An antibiotic SF-1942 substance produced by cultivating an SF-1942 substance producing strain of the genus Streptomyces in a nutrient medium under aerobic conditions to produce and accumulate the SF-1942 substance in the nutrient medium and isolating the SF-1942 substance from the fermentation broth followed by purification and a process for the production of the antibiotic SF-1942 substance. The SF-1942 substance is effective as an antimicrobial agent and an antitumor agent against Sarcoma 180 tumor cells in mice.

Antibiotic SF-1942 substance and process for production of the same

A new antibiotic SF-1771 substance is produced by cultivating a new strain, Streptomyces toyocaensis SF-1771, in a liquid culture medium under aerobic conditions. This antibiotic may be isolated from the fermentation broth by treating the broth filtrate with a synthetic adsorbent resin for adsorption of the active compound and eluting the resin with an aqueous alcohol or aqueous acetone, followed by chromatographic purification. SF-1771 substance is a copper-containing antibiotic which shows antibacterial activity against Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus subtilis. Removal of the copper component from SF-1771 substance by treatment with hydrogen sulfide, an alkali metal sulfide or a copper-chelating agent gives SF-1771-B substance containing no copper component which shows antibacterial activity as high as but a toxicity lower than SF-1771 substance.

Antibiotics SF-1771 substance and SF-1771-B substance as well as the

New antibiotics SF-1130-x.sub.1 substance and SF-1130-x.sub.2 substance are produced by cultivating a microorganism Streptomyces myxogenes SF-1130 now deposited under FERM-P. 676 and ATCC. 31305 in a liquid culture medium under aerobic conditions, and these antibiotics may be isolated from the fermentation broth and are useful as an activator for enhancing the host defense system in living animals. The activity of these antibiotics may be improved when used in combination with one or more of maltose, maltotriose, maltotetraose, maltopentaose, maltohexaose and maltoheptaose.

Antibiotics SF-1130-x.sub.1 and -x.sub.2 substances and production and

A new antibiotic designated as SF-1623 substance exhibiting a useful antibacterial activity against gram-negative bacteria is now produced by cultivating a new strain ATCC 21999 of the known species Streptomyces chartreusis. The SF-1623 substance in the form of its an alkali metal salt may be recovered from the culture when the cultivation is effected under aerobic conditions in the presence of an alkali metal thiosulfate.

Antibiotic SF-1623 substance and the production thereof

Antibiotic SF-1623 substance

This invention relates to a process for preparing a cephamycin type antibiotic substance which comprises cultivating a microorganism belonging to the genus Streptomyces under aerobic conditions and a primary object of this invention is to provide a process for preparing the said product on a simple and industrial scale.

Growing community of inventors

Tokyo, Japan

Michio Kojima